A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages

Objectives: Interleukin (IL)-6 inhibitors are administered to treat patients hospitalized with COVID-19. In 2021, due to shortages, different dosing regimens of tocilizumab, and a switch to sarilumab, were consecutively implemented. Using real-world data, we compare the effectiveness of these IL-6 i...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Maaike C. Swets, Rob J. Moss, Flip Kor, Doranne Hilarius, Dirk Jan A.R. Moes, Willemijn EM Berkhout, Leon M. van den Toorn, Niels C. Gritters van den Oever, Renee de Valk, Frits R. Rosendaal, Nicole Hunfeld, Geert H. Groeneveld, Mark G.J. de Boer
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2023-04-01
Ráidu:	International Journal of Infectious Diseases
Fáttát:	IL-6 inhibitor COVID-19 SARS-CoV-2 Tocilizumab Sarilumab
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S1201971223000413
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!